HeMemics Biotechnologies
HeMemics: Rapid, low-cost biosensor solutions for real-time infectious disease detection.
Founded
2009HeMemics: Rapid, low-cost biosensor solutions for real-time infectious disease detection.
HeMemics Biotechnologies, founded with a mission to revolutionize infectious disease detection, offers rapid, low-cost biosensor solutions. The company’s core vision is to empower healthcare providers with the ability to identify pathogens in 60 seconds or less, facilitating real-time outbreak alerts. Their product lineup includes portable readers and single-use biochips equipped with graphene-based sensors, capable of detecting molecular, antigen, and antibody targets. HeMemics focuses on delivering lab-quality testing performance in a handheld format, making critical diagnostic tools accessible in various settings.
Notable figures associated with HeMemics include key investors and experts in biotechnology and healthcare innovation. The company has achieved significant milestones, including the development and patenting of their bio preservative technology and graphene-based sensors. HeMemics' impact is evident in its potential to transform public health responses by providing rapid diagnostics, thereby enhancing the ability to manage and contain infectious diseases effectively.
Companies similar to HeMemics Biotechnologies include Biomeme, NanoSpy, Innovative Biosensors and Nanomed.
HeMemics Biotechnologies was founded in 2009.
HeMemics Biotechnologies' headquarters is located in Gaithersburg, MD, US.
HeMemics Biotechnologies' most recent funding round was for $2M (USD) in May 2023.
As of May 25, 2023, HeMemics Biotechnologies has disclosed funding of $5.1M (USD). Undisclosed round amounts are excluded.
HeMemics Biotechnologies has 16 employees as of Feb 5, 2024.
Nanomed
